Aberrant expression of interleukin-7 (IL-7) and its signalling complex in human breast cancer

Al-Rawi, Mahir A.; Rmali, Khaled A.; Watkins, Gareth; Mansel, Robert Edward; Jiang, Wen Guo

doi:10.1016/j.ejca.2003.10.016

Cited by 81 publications

(68 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In one study IL-7 mRNA and protein could not be detected in breast cancer (Maeurer et al, 1997). In another study, however, the levels of IL-7, IL-7R, and its signalling intermediates were shown to be overexpressed in the aggressive breast tumors (Al-Rawi et al, 2004). Moreover, there are multifaceted aspects of G-CSF function to be considered in relation to tumor progression and defence against breast tumors.…”

Section: Discussionmentioning

confidence: 99%

“…Production of IL-7 by human solid tumors can have an effect on tumorigenesis process as shown in specific types of lymphomas and leukemias (Roato et al, 2006). It has been shown that IL-7 is a potent growth factor for both endothelial and breast cancer cells (Al-Rawi et al, 2004). This has led to the proposal that IL-7 may influence breast cancer biology, in terms of development and progression.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum Levels of G-CSF and IL-7 in Iranian Breast Cancer Patients

Bordbar

Malekzadeh²,

Ardekani³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Introduction: Breast cancer cells and tumor stroma produce different cytokines and soluble factors. Cytokines, while playing crucial roles in immune responses to tumors, also favour tumor growth and progression. IL-7 and G-CSF are two cytokines that may exert influences on the pathophysiology of breast cancer. Materials and Methods: Sera were collected from 136 females with breast cancer before receiving chemotherapy or radiotherapy. The control group comprised of 60 healthy age-matched females without any acute or chronic diseases with no family history of breast cancer. Serum levels of IL-7 and G-CSF were measured by commercial enzyme linked immunosorbent assay. Results: While there was no significant difference in the level of G-CSF between patients (92.81±594.54 pg/ml) and controls (0.00 pg/ml), G-CSF level in sera of patients with advanced stages of breast cancer was elevated compared to early stages (p=0.0001). Moreover, the highest level of G-CSF was seen in patients with N3 phase tumors (p=0.0001). IL-7 was slightly but not significantly higher in the control group (0.04±0.11 pg/ml) in comparison with patients (0.02±0.10 pg/ml). Interestingly, a significant increase in the level of IL-7 in patients with skin involvement was observed (p=0.001). Conclusion: Our results showed an elevation of G-CSF in sera of patients with advanced stages of tumor, while IL-7 elevation correlated with skin involvement of breast cancer. IL-7 can be produced by keratinocytes in skin tissue and may be involved in the pathologic establishment of metastatic tumor cells in skin.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Serum Levels of G-CSF and IL-7 in Iranian Breast Cancer Patients

Bordbar

Malekzadeh²,

Ardekani³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…In breast cancer patients, aberrant expression of IL-7 and its signaling intermediates have also been related to a poor prognosis (17). It was suggested that IL-7 affects breast tumors by acting as a growth factor for both endothelial and breast cancer cells and by promoting lymphangiogenesis and metastasis (17,18). In contrast, transfection of IL-7 in an ovarian cancer cell line reduced tumorgenicity probably by activation of lymphokineactivated killer cells (12).…”

Section: Discussionmentioning

confidence: 99%

Serum Cytokine Profiling as a Diagnostic and Prognostic Tool in Ovarian Cancer: A Potential Role for Interleukin 7

Lambeck¹,

Crijns²,

Leffers³

et al. 2007

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: To evaluate if serum cytokine levels could be used as diagnostic or prognostic markers in ovarian cancer. Experimental Design: A cytokine bead array was done to simultaneously analyze 14 cytokines in the sera of 187 ovarian cancer patients with complete clinicopathologic data and follow-up, 45 patients with benign ovarian tumors, and 50 healthy controls. Serum levels of the well-known serum tumor marker CA-125 were routinely measured in all patients. Results: Serum levels of CA-125, interleukin 6 (IL-6), IL-7, and IL-10 were elevated in ovarian cancer patients compared with patients with benign ovarian tumors. Analyzing the cytokines in combination with CA-125 showed that a combination of IL-7 and CA-125 serum levels could accurately predict 69% of the ovarian cancer patients, without falsely classifying patients with benign pelvic mass. The cytokines IL-6, IL-7, IL-8, IL-10, monocyte chemotactic protein-1 (MCP-1), and IP-10 and CA-125 were associated with disease-free and overall survival in univariate analysis. In multivariate analysis, IL-7 and IP-10 were independent predictors of overall survival, although after inclusion of the clininopathologic parameters, only stage and residual disease remained as independent predictors of survival. Conclusions: IL-7 levels were found to be strongly associated with ovarian cancer and could be used in combination with CA-125 to distinguish between malignant and benign ovarian tumors.

show abstract

“…After 3 days, the mice were killed with halothane and the injection sites (ten Matrigel pockets in each group) were dissected. Sections from each pocket were stained immunohistochemically using antivon Willebrand factor (antifactor VIII) (goat polyclonal; Santa Cruz Biotechnology) and rabbit polyclonal anti-LYVE-1 15 , as described previously 13 . The number of tubules and the intensity of immunostaining were assessed in six random fields per slide by two independent observers and any disagreement was resolved by discussion and re-evaluation of the slides.…”

Section: In Vivo Lymphangiogenesis Modelmentioning

confidence: 99%

“…Recently, interleukin (IL) 7, a pleiotropic and antiapoptotic factor, has been identified as a putative lymphangiogenic growth factor in endothelial cells 12 . IL-7 expression has been found to be significantly higher in node-positive breast cancer and in tumours with a poor prognosis 13 . Furthermore, activation of IL-7 receptor (IL-7R) on breast cancer cells by IL-7 results in significant cell growth 14 .…”

Section: Introductionmentioning

confidence: 99%